Comparative quantitative evaluation of the XIAP, survivin & Ki67 transcript levels in urine & tissue samples of bladder cancer patients.

Slides:

Advertisements

Similar presentations

Transitional Cell Carcinoma of the Urinary Tract

Advertisements

The Role of Urine cytology in the investigation of Haematuria? B Barrass Audit Meeting 17 th May 2006.

PROSTATE CANCER Dr Samad Zare Assistant Proffesor of Urology Shaheed Sadoughi University of Medical Sciences.

Haematuria and Urinary Tract Tumours

Bladder tumors 3 times more common in men

Tumor Markers Lecture one By Dr. Reem Sallam. Objectives  To briefly introduce cancers, their incidence, some common terms, and staging system.  To.

The long term outcome of high risk non-muscle invasive bladder cancer. F Thomas, N Rubin, J Goepel, D Rosario, MF Abbod, JWF Catto. Academic unit of Urology,

Tab.1: Relative transcript levels of prostate-related genes in prostate tissues and cell lines (zmol gene/zmol TBP) * Data for the prostate-related genes.

PREOPERATIVE PLASMA CONCENTRATION OF MMP-9/TIMP-1 COMPLEXES IS NOT ASSOCIATED WITH DISEASE OUTCOME IN PRIMARY BREAST CANCER (N=483) Anne-Sofie Schrohl.

M Ravanbod Medical oncologist Bushehr – 11/91 A 50 y/o white man comes for check up and wants to discuss about prostate cancer. Negative family history.

Treatment options for locally recurrent Prostate Cancer Giuseppe Simone Mediterranean School of Oncology Roma

Eleni Galani Medical Oncologist

EPCA: A silver lining for early diagnosis of prostate cancer GHOLAMREZA POURMAND, MD Professor of Urology Urology Research Center Tehran University of.

. Quantitative multi-gene expression profiling of primary prostate cancer* Meye A, Schmidt U 1, Füssel S, Koch R, Baretton GB, Lohse A, Tomasetti S, Froehner.

AGO-OVAR DESKTOP III (Protocol AGO - OVAR OP.4)

Adult Medical-Surgical Nursing

Introduction & Objectives: This study describes the evaluation of the expression pattern of prostate-specific transcripts in 106 matched prostate tissues.

Tumor Biomarkers are high lightened Once Again Cancer Facts Cancer etiology Tumor Genetics Tumor MarkersLocation Classification Uses methods of detection.

Should I have that blood test for Prostate Cancer?

Surrogate End point for Prostate Cancer- Specific Mortality After RP or EBRT A D’Amico J Nat Ca Inst 95,

Role of Biomarkers in Management of Prostate Cancer Dr. Angela Amayo Specialist Pathologist 13 th April 2012.

Na + /H + exchanger regulatory factor 1 (NHERF1) and angiogenesis in familial breast cancer A Mangia*, A Malfettone*, C Salvatore**, B Stea*, G Simone**

The PCA3 Assay improves the prediction of initial biopsy outcome and may be indicative of prostate cancer aggressiveness de la Taille A, Irani J, Graefen.

S. Fuessel 1, S. Unversucht 1, R. Koch 2, G. Baretton 3, A. Lohse 1, S. Tomasetti 1, M. Haase 3, M. Toma 3, M. Froehner 1, A. Meye 1, M.P. Wirth 1 1 Department.

Comparative quantitative evaluation of the XIAP, survivin & Ki67 transcript levels in urine & tissue samples of bladder cancer patients Woei-Yun Siow &

Fecal calprotectin DR Amin Eftekhari.

The Treatment of the Axilla in the North of England Cancer Network. Henry Cain ST7 North Tyneside.

Materials & Methods prospective study: February January 2007 prospective study: February January 2007 inclusion criteria: inclusion criteria:

Improved Detection of Bladder Cancer in Diagnosis and Surveillance Patients Using a Point-of-Care Proteomic Assay Barry Stein, M.D. G. Katz, M.D. NMP22.

Management of T1G3 Bladder cancer Dr Charles Chabert.

Table S1. Demographics and Patient Pathology Results Total number of patients40 Male (%)29 (72%) Female (%)11 (28%) Age Range47 – 86 Median Age70 Organ.

4. DPKK Workshop in Bonn/Königswinter Quantitative multi-gene expression analyses on paired prostate tissue samples from radical prostatectomies.

Bladder cancer is the second most common cancer of the genitourinary tract. The incidence is higher in whites than in African Americans. The average age.

EORTC scores of recurrence and progression in a Romanian cohort First author: Anda Ştefan Co-authors: Radu Mihail Boja, PhD Ovidiu Ioan Golea, PhD Ladislau.

Neoplasms of the bladder

Materials & Methods prospective study: February 2006 – December 2008 prospective study: February 2006 – December 2008 inclusion criteria: inclusion criteria:

Clinical variables, pathological factors, and molecular markers for enhanced soft tissue sarcoma prognostication G. Lahat, B. Wang, D. Tuvin, DA. Anaya,

Should We Screen for Bladder Cancer in a High Risk Population: A Cost per Life-Year Saved Analysis? Yair Lotan, Robert S. Svatek, Arthur I. Sagalowsky.

Poster Title ABSTRACT #59 Cell cycle progression genes differentiate indolent from aggressive prostate cancer. Steven Stone 1 Jack Cuzick 2, Julia Reid.

Tumor clock protein PER2 as a determinant of survival in patients (pts) receiving oxaliplatin-5-FU- leucovorin as 1st line chemotherapy for metastatic.

CHFR METHYLATION AS AN EPIGENETIC MARKER FOR RECURRENCE OF COLON CANCER M. D. Anderson Cancer Center, Houston, Texas Motofumi Tanaka, Salil Sethi, Donghui.

Understanding Cancer and Related Topics

Blood and Tissue Based Molecular Signatures in Predicting Prostate Cancer Progression Tarek A. Bismar, MD Professor, University of Calgary Departments.

Anaplastic thyroid cancer based on ATA guideline for Management of Patients with ATC. Thyroid. 2012;22: R3 이정록.

Annals of Oncology 24: 2206–2223, 2013 R3 조영학

Statistical Considerations for Detection of Bladder Cancer by Microsatellite Analysis (MSA) of Urinary Sediment: Multi-Institutional Study Presentation.

Bladder Cancer Mark Browning, M.D. ‘ IUSME.

Prostate cancer update Suresh GANTA Consultant urological surgeon Manor Hospital.

Adjuvant and Neoadjuvant Therapy in Non- Small Cell Lung Cancer Seminars in Oncology 2oo5;32 (suppl 2):S9-S15 Kyung Hee Medical Center Department of Thoracic.

HE-4 TRIAL Prospective phase II trial on the prognostic and predictive value of HE-4 regression during neoadjuvant chemotherapy for advanced ovarian, Fallopian.

Urothelial tumors Tumors in the collecting system above the bladder are relatively uncommon. These tumors are classified into : 1 benign papilloma. 2-papillary.

The New Quantitative Point of Care Assay UBC-Rapid: Evaluation in Bladder Cancer Diagnosis and Relevant Clinical Interferences Gerson Lüdecke*, Arne Hauptmann,

Common pitfall in Oncology Luangyot Thongthieang, MD MEDICAL ONCOLOGY UNIT INTERNAL MEDICINE, KHONKAEN HOSPITAL.

Canadian Undergraduate Urology Curriculum (CanUUC): Hematuria

UROVYSION® FISH Urine Cytology Assessment: Principles and Concepts

SURGICAL ONCOLOGY AND TUMOR MARKERS

Per-Anders Abrahamsson Department of Urology Malmö University Hospital

Prostate Cancer Screening in the fit Chilean Elderly: a head to head comparison of total serum PSA versus age adjusted PSA versus primary circulating prostate.

* Potential use of HP and AMBP in urine for the screening of prostate cancer Sanja Kiprijanovska1, Selim Komina2, Gordana Petrusevska2,

Volume 55, Issue 3, Pages (March 2009)

Tertiary cytoreductive surgery in recurrent epithelial ovarian cancer:

Volume 63, Issue 6, Pages (June 2013)

New Trends in Bladder Cancer Management

The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.

CEACAM1: A Novel Urinary Marker for Bladder Cancer Detection

Volume 55, Issue 3, Pages (March 2009)

Might Men Diagnosed with Metastatic Prostate Cancer Benefit from Definitive Treatment of the Primary Tumor? A SEER-Based Study Stephen H. Culp, Paul.

Role of cytokeratins in the diagnosis and prognosis of the bladder cancer Giorgi Adeishvili MD Multiprofile clinic Consilium Medulla.

Urinary bladder cancer

Presentation transcript:

Comparative quantitative evaluation of the XIAP, survivin & Ki67 transcript levels in urine & tissue samples of bladder cancer patients

Introduction Bladder cancer (BCa)- 5th commonest cancer in European men & 6th leading cause of death Cystoscopy & urine cytology - current gold standards for diagnosis & surveillance of BCa Ideal tumour marker for non-invasive diagnosis & surveillance does not yet exist

Introduction Survivin inhibitor of apoptosis protein (IAP) that is selectively over- expressed in most human malignancies Objectives – determine suitability of survivin as diagnostic, surveillance (and prognostic) marker of BCa –compare the utility of survivin to other potential tumour markers e.g. Ki67 and XIAP

Materials & Methods Prospective study Single, tertiary level referral centre January - June 2006 Inclusion criteria –patients undergoing transurethral resection (TUR) for newly diagnosed BCa, recurrent BCa & cystoscopically suspicious bladder lesions

Materials & Methods Exclusion criteria –Patients with PCa, IDC, UTI Controls –BPH patients –Cystitis patients –Healthy volunteers

Materials & Methods BCa patients –Pre-operative urine sample –Intra-operative tumour tissue & “normal appearing” bladder mucosa –Post-operative urine sample (1 POD) –Above repeated for every session of TUR Controls –1 urine sample from each

Materials & Methods Quantitative evaluation of urinary & tissue levels of survivin, XIAP & Ki67 Normalized ratios of survivin, XIAP & Ki67 correlated with clinicopathological data

Results Reference genes used – HPRT & TBP Negative correlation between reference gene expression & urinary contamination by RBCs & WBCs

BCa patients 65 recruited 6 pts with both BCa & Pca, excluded from analysis > 59 pts analysed Age (median)= 69yrs (34 – 89) M:F= 39: 20 (66.1% : 33.9%) Newly dx: BCa recurr= 54: 5 (91.5% : 8.5%) PSA (median; 36 pts)= 0.90 (0.16 – 12.54)

BCa patients diagnosis (59) No tumour (11) 18.6% Superficial (38) = Ta+T1 64.5% Invasive (10) = T2 16.9% diagnosis (59) No tumour (11) 18.6% Low (14) = G1 23.8% High (34) = G2+G3 57.6%

BCa patients cis –Pos: neg= 5: 54 (8.5% : 91.5%) –All with cis harbour high grade (G2/ G3) disease as well Cytology –Sensitivity= 65.2%; Specificity= 80.0% –PPV= 83.3%; NPV= 60.0% benignatypialowhighNA 9 (15.3%)2 (3.3%)9 (15.3%)18 (30.5%)21 (35.6%)

BCa patients 59 primary TURBT 42 second op (33 sec TUR, 9 cystec) 8 third op (6 tertiary TUR, 2 cystec)

Controls BPHCystitisHealthy yrs (52-85)64 yrs (19-85)31 yrs (18-59) PSA median 2.9 (0.3 – 33.9) M : F 3 (23.1%) :10 (76.9%) M : F 7 (25.9 %) :20 (74.1 %)

Tumor markers between BCa patients & controls Clinical diagnosis Ki67/ HPRT Ki67/ TBP XIAP/ HPRT XIAP/ TBP SVV/ HPRT SVV/ TBP Bca (48) (positive histo) No tumor (11) (negative histo) BPH (53) Cystitis (13) Healthy (27) Median values presented

Ki67

XIAP

Survivin

Tumor markers vs BCa stage BT pri TUR (59) Ki67/ HPRT Ki67/ TBP XIAP/ HPRT XIAP/ TBP SVV/ HPRT SVV/ TBP No tumor (11) Superficial (38) Invasive (10) Median values presented

Ki67

XIAP

Survivin

Tumor markers vs BCa grade BT pri TUR (59) Ki67/ HPRT Ki67/ TBP XIAP/ HPRT XIAP/ TBP SVV/ HPRT SVV/ TBP No tumor (11) Low grade (14) High grade (34) Median values presented

Ki67

XIAP

Survivin

Tumor markers between first & second TURBT BT paired urine samples (33) Ki67/ HPRT Ki67/ TBP XIAP/ HPRT XIAP/ TBP SVV/ HPRT SVV/ TBP Op Op Median values presented

Ki67

XIAP

Survivin

Tumor markers for unpaired tissue samples tissue samples Ki67/ HPRT Ki67/ TBP XIAP/ HPRT XIAP/ TBP SVV/ HPRT SVV/ TBP Tumor tissue (26) Tumor free (27) Median values presented

Ki67

XIAP

Survivin

Tumor markers for paired tissue samples Paired tissue samples (13) Ki67/ HPRT Ki67/ TBP XIAP/ HPRT XIAP/ TBP SVV/ HPRT SVV/ TBP Tumor tissue 1,735,996,4213,610,531,11 Tumor free 1,522,018,2214,260,350,41 Median values presented

Ki67

XIAP

Survivin

Ratio Tu / Tf Paired tissue samples (13) Ki67/ HPRT Ki67/ TBP XIAP/ HPRT XIAP/ TBP SVV/ HPRT SVV/ TBP Median >18 (61.5%) 10 (76.9%) 3 (23.1%) 6 (46.2%) 8 (61.5%) <15 (38.5%) 3 (23.1%) 10 (76.6%) 7 (53.8%) 5 (38.5%)